Kaya Holdings (KAYS) Total Non-Current Liabilities (2014 - 2025)
Kaya Holdings (KAYS) recorded quarterly Total Non-Current Liabilities of $385742.0 in Q3 2025, down 95.92% quarter-over-quarter from $9.5 million in Q2 2025, and down 95.87% on a YoY basis from $9.3 million in Q3 2024.
Kaya Holdings (KAYS) Total Non-Current Liabilities (2014 - 2025) Analysis & Trends
Kaya Holdings' Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $385742.0 for Q3 2025.
- In Q3 2025, Total Non-Current Liabilities fell 95.87% year-over-year to $385742.0; the TTM figure through Sep 2025 stood at $385742.0 (down 95.87% YoY), while the FY2024 annual figure was $9.2 million, up 7.94% from the prior year.
- Total Non-Current Liabilities was $385742.0 for Q3 2025 at Kaya Holdings, down from $9.5 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $9.5 million in Q2 2025 to a low of $385742.0 in Q3 2025.
- Historically, Total Non-Current Liabilities has averaged $7.9 million across 5 years, with a median of $8.0 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities gained 15.1% in 2022, then sank 95.87% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $7.9 million in 2021, then advanced by 1.8% to $8.0 million in 2022, then advanced by 6.63% to $8.6 million in 2023, then gained by 7.94% to $9.2 million in 2024, then slumped by 95.83% to $385742.0 in 2025.
- The last three Total Non-Current Liabilities figures came in at $385742.0 (Q3 2025), $9.5 million (Q2 2025), and $9.3 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | Kaya Holdings | - | - | 5,370.00 | 385,742.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 385,742.00 |
| Jun 30, 2025 | 9.45 Mn |
| Mar 31, 2025 | 9.33 Mn |
| Dec 31, 2024 | 9.24 Mn |
| Sep 30, 2024 | 9.34 Mn |
| Jun 30, 2024 | 8.99 Mn |
| Mar 31, 2024 | 8.79 Mn |
| Dec 31, 2023 | 8.56 Mn |
| Sep 30, 2023 | 8.45 Mn |
| Jun 30, 2023 | 8.37 Mn |
| Mar 31, 2023 | 8.03 Mn |
| Dec 31, 2022 | 8.03 Mn |
| Sep 30, 2022 | 7.96 Mn |
| Jun 30, 2022 | 7.98 Mn |
| Mar 31, 2022 | 7.91 Mn |
| Dec 31, 2021 | 7.89 Mn |
| Sep 30, 2021 | 6.98 Mn |
| Jun 30, 2021 | 6.94 Mn |
| Mar 31, 2021 | 6.99 Mn |
| Dec 31, 2020 | 6.92 Mn |